Please assess the completion status of the following clinical trial:

Trial Title: Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. age: 18-75 years, male or female.~2. Histologically or cytologically confirmed Squamous Cell Carcinoma of the Esophagus, locally advanced, unresectable disease, recurrent or Metastatic disease.~3. Fail to the first-line standard therapy.~4. Measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.~5. Can provide either a newly obtained or archival tumor tissue sample.~6. ECOG 0-1.~7. Life expectancy of greater than 12 weeks.~8. Adequate organ function.~9. Female: child bearing potential, a negative urine or serum pregnancy test result within 72 h before study treatment. Participants of reproductive potential must be willing to use adequate contraception for the course of the study through 3 months after the last dose of SHR-1210 or through 180 days after the last dose of docetaxel or irinotecan.~10. Patient has given written informed consent.~Exclusion Criteria:~1. Has a known additional malignancy within the last 5 years before study treatment with the exception of curatively treated basal cell and squamous cell carcinoma of the skin and/or curatively resected in-situ cervical and/or breast cancers.~2. Known central nervous system (CNS) metastases.~3. Subjects with any active autoimmune disease or history of autoimmune disease.~4. Uncontrolled clinically significant heart disease, including but not limited to the following: (1) \> NYHA II congestive heart failure; (2) unstable angina, (3) myocardial infarction within the past 1 year; (4) clinically significant supraventricular arrhythmia or ventricular arrhythmia requirement for treatment or intervention;~5. Active infection or an unexplained fever \> 38.5°C before two weeks of randomization (subjects with tumor fever may be enrolled at the discretion of the investigator);~6. History of Interstitial Pneumonia or received Corticosteroids for non-infectious pneumonitis.~7. Known Human Immunodeficiency Virus (HIV) infection, active Hepatitis B or Hepatitis C.~8. BMI, \<18.5mg/m2 or ≥10% weight lost before screening.~9. Prior therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) agent.~10. Known history of hypersensitivity to macromolecular protein preparation or any components of the SHR-1210 formulation, allergy, hypersensitivity, or contraindication to docetaxel, or irinotecan.~11. Concurrent medical condition requiring the use of cortisol ( \>10mg/day Prednisone or equivalent dose) or other systematic immunosuppressive medications within 14 days before the study treatment. Except: inhalation or topical corticosteroids. Doses \> 10 mg/day prednisone or equivalent for replacement therapy.~12. Has received prior anti-cancer monoclonal antibody (mAb), chemotherapy, targeted small molecule therapy, or radiation therapy within 4 weeks prior to study Day 1 or not recovered from adverse events due to a previously administered agent.~13. Currently participating or has participated in a study within 4 weeks of the first dose of study medication.~14. Received a live vaccine within 4 weeks of the first dose of study medication.~15. Pregnancy or breast feeding.~16. According to the investigator, other conditions that may lead to stop the research.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- camrelizumab (Type: EXPERIMENTAL): None
- Investigator's Choice of Standard Therapy (Type: ACTIVE_COMPARATOR): Docetaxel or Irinotecan

Based on this trial design, predict the completion outcome and termination type (if applicable).